DaVita’s stock has soared over 120% in six months, fueled by strong quarterly results—but beneath the surface, treatment volume hasn’t grown much, hinting at rising competition or pricing pressure. Analysts forecast just 2.6% revenue growth next year, slower than their five-year average, while falling free cash flow margins signal rising costs. Despite a seemingly reasonable valuation, the business quality doesn’t justify a “buy” right now—better opportunities may lie elsewhere in the market.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
